baber/WOPTO huggingface dataset:
Patent NZ-613079-A (NZ)
Title: Encased tamper resistant controlled release dosage forms
Inventor: HUANG HAIYONG HUGH
IPC: C07D221/28
Filed: 2011-12-21
Abstract: The disclosure relates to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material comprising polyethylene oxide having an average molecular weight from about 300,000 to about 10,000,000; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material comprising polyethylene oxide having an average molecular weight from about 1,000,000 to about 10,000,000. The molecular weight of the polyethylene oxide in the first matrix material is lower than the molecular weight of the polyethylene oxide in the second matrix material. The amount of opioid analgesic released from the dosage form may be proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in- vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 degrees C. The first and second matrix material may comprise polyethylene oxide and the opioid analgesic may be selected from codeine, hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone or tramadol. The disclosure also relates to methods of producing the solid controlled release dosage form.
Patent NZ-618373-A (NZ)
Title: Hypertension and hyperuricemia
Inventor: MINER JEFFREY
IPC: C07D285/24
Filed: 2012-05-22
Abstract: Disclosed herein is the use of a combination of a thiazide diuretic; the organic anion transporter 4 (OAT4) inhibitor 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid (lesinurad) or a pharmaceutically acceptable salt thereof and allopurinol in the manufacture of a medicament for use in the treatment of gout, hyperuricemia or reducing serum uric acid levels in a patient suffering from hypertension. The thiazide diuretic is selected from hydrochlorothiazide, bendroflumethiazide, benzothiadiazine, hydroflumethiazide, clorothiazide, methyclothiazide, polythiazide, chlorthalidone, metolazone, indapamide, bumetanide, ethacrynic acid, furosemide or torsemide.
Patent NZ-631360-A (NZ)
Title: Apparatus for exhausting air
Inventor: KEVIN HARRIS
IPC: F24F13/02
Filed: 2013-02-18
Abstract: Disclosed herein is an apparatus for exhausting air from a space. The space may comprise the interior space(s) of buildings such as hospitals, enclosed shopping malls, warehouses, factories, high rise buildings, etc. The apparatus comprises at least a first discharging arrangement in the form of return and supply air ducts of an air handling unit (AHU, 16). The apparatus also comprises a second discharging arrangement in the form of a smoke exhaust box (18). The return air duct is arranged to receive an air stream discharged from the space and is able to be isolated from the smoke exhaust box. Upon isolation of the return air duct, the smoke exhaust box is able to receive and discharge an air stream (e.g. a smoke-filled or contaminated air stream) from the space. The second discharging unit is cantilevered to the first unit to reduce the footprint of the apparatus on the roof to which it is attached.
Patent NZ-705759-A (NZ)
Title: Rsv antiviral compounds
Inventor: COOYMANS LUDWIG PAUL
IPC: A61K31/407
Filed: 2013-10-15
Abstract: Inhibitors of RSV replication of formula RI including stereochemically isomeric forms, and salts or solvates thereof, wherein R22, W, Q, V, Z p,s,and Het have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other RSV inhibitors, in RSV therapy.
Patent NZ-706249-A (NZ)
Title: Stable injectable pharmaceutical composition of epinephrine or salts thereof
Inventor: JAIN GIRISH KUMAR
IPC: A61K47/02
Filed: 2013-05-03
Abstract: The present invention refers to a stabilized injectable pharmaceutical composition of epinephrine or salts thereof comprising sodium metabisulfite, wherein the ratio of the amount of epinephrine or salt thereof to sodium metabisulfite in the composition ranges from about 1 :0.005 to about 1:1.5 by weight. It has been observed that stable injectable epinephrine compositions with excellent storage stability and substantially free of overages can be prepared using sodium metabisulfite in said ratios. Particularly, it was found that using sodium metabisulfite in said ratios controls levels of adrenaline sulfonate impurity in said pharmaceutical compositions.
Patent NZ-709359-A (NZ)
Title: Synergistic weed control from applications of aminocyclopyrachlor and picloram
Inventor: POSADA EDUARDO
IPC: A01P13/02
Filed: 2013-12-09
Abstract: Disclosed herein are herbicidal compositions comprising a synergistically herbicidal effective amount of (a) aminocyclopyrachlor, or an agriculturally acceptable salt or ester thereof, and (b) picloram, or an agriculturally acceptable salt or ester thereof. Also disclosed herein are methods of controlling undesirable vegetation, which comprise applying to vegetation or an area adjacent the vegetation or applying to soil or water to prevent the emergence or growth of vegetation (a) aminocyclopyrachlor, or an agriculturally acceptable salt or ester thereof, and (b) picloram, or an agriculturally acceptable salt or ester thereof, wherein (a) and (b) are each added in an amount sufficient to produce a synergistic herbicidal effect.
Patent NZ-710383-A (NZ)
Title: A novel formulation of diclofenac
Inventor: MEISER FELIX
IPC: B01J2/00
Filed: 2010-04-23
Abstract: The present disclosure relates to a unit dose of a pharmaceutical composition containing diclofenac acid wherein the particles of diclofenac acid have a median particle size on a volume average basis of less than 500 nm and greater than 25 nm, wherein the unit dose when tested in vitro by USP Apparatus I (Basket) method of U.S. Pharmacopoeia at 100 rpm at 37.degree.C. in 900 ml of 0.05% sodium lauryl sulfate in citric acid solution buffered to pH 5.75 and has a dissolution rate of diclofenac acid such that at least 70%, by weight, is released by 60 minutes. Also disclosed are methods of making the same.
Patent NZ-712853-A (NZ)
Title: Method and apparatus for processing carbonaceous material
Inventor: WINTER JOHN DAVID
IPC: C10J3/00
Filed: 2014-02-28
Abstract: An apparatus 100 and method for processing carbonaceous material is provided. Known gasification processes use moving bed reactors, fluid bed reactors, and entrained flow reactors. Each process has drawbacks including high production of pyrolysis products, reduced thermal efficiency, restrictions on the size of the feed particles, high temperature demands and high oxygen demands. The apparatus provided herein has a reactor vessel 130 with a plurality of solids medium ingress apertures 142a, 142b, 142c, 142d for receiving controlled fluid flow of heated solids medium and a feed material ingress aperture 131. The ingress apertures are spaced along the flow path of the reactor vessel for forming distinct zones based on temperature. The reactor vessel has a syngas egress aperture 150 and at least one egress aperture 146 for egress of processed carbonaceous solid material and spent solids medium. The method includes allowing the heated solids medium to transfer heat to the feed material in the reactor vessel 130 to produce syngas and a processed carbonaceous solid material. The syngas is allowed to exit the reactor vessel through the syngas egress aperture 150. The processed carbonaceous solid material and spent solids medium are removed through the at least one egress aperture.
Patent NZ-713878-A (NZ)
Title: Interlocking and shock attenuating tiling systems
Inventor: BROWN GRAHAM KEVIN
IPC: E04F15/22
Filed: 2014-04-14
Abstract: A shock attenuating tile assembly is provided to form a ground covering that is suitable for fall risk areas such as playgrounds. The shock attenuating tile preferably includes a plate having an upper side for bearing a load and a plurality of shock absorbing modules depending from an underside of the plate. Each of the shock absorbing modules is integrally formed with the plate. An interlocking floor tile assembly may be provided in conjunction with the shock attenuating tile assembly that includes a first repeating array of spaced apart first tiles interconnected by first bridge portions wherein the first tiles and the first bridge portions define first spaces therebetween. The interlocking floor tile assembly may also include a second repeating array of spaced apart second tiles interconnected by second bridge portions wherein the second tiles and the second bridge portions define second spaces therebetween. The second tiles are received in the first spaces and the first tiles are received in the second spaces.
Patent NZ-719941-A (NZ)
Title: Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
Inventor: DONG YIZHOU
IPC: C12N15/87
Filed: 2012-10-26
Abstract: Described herein are compounds and compositions that are characterized by the Markush formulae (I), (II), (III), (IV), (V), and (VI) underneath, where at least one terminal amino group is further functionalized by bearing a group of type (i), (ii), or (iii). Such compounds are obtained by reacting a terminal or internal amino group with epoxides, acrylates, or aldehydes bearing lipophilic groups. The resulting amino acid, peptide, polypeptide-lipids (named “APPLs” in the application) are deemed useful as drug delivery systems including nucleotide delivery to cells.
Patent NZ-720006-A (NZ)
Title: Dispenser cap arrangement
Inventor: DUIGNAN CATHAL
IPC: B65D39/00
Filed: 2012-10-31
Abstract: A dispenser cap (71) for enclosing a portion of a dispenser of a medicament, the dispenser cap comprising: a hollow body having a lower open end for engaging with a body portion of a dispenser, and an upper open end for receiving a dispenser cap closure device for closing the upper open end. The upper open end comprises an engageable portion for engaging with a dispenser cap closure device for closing the upper open end of the hollow body and an upper surface of the dispenser cap comprises a limiting means (teeth 81) for preventing rotation in either direction of the cap closure device when engaged with the dispenser cap.
Patent NZ-731658-A (NZ)
Title: Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
Inventor: KIM HYUN UK
IPC: C07K14/605
Filed: 2013-11-06
Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the invivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection. In addition, the oxyntomodulin conjugate of the invention comprises oxyntomodulin linked to an immunoglobulin Fc region, and thus has a large molecular weight, prolonged physiological activity, and excellent storage stability, compared to native oxyntomodulin.
Patent NZ-733110-A (NZ)
Title: Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
Inventor: DAI WEIGUO
IPC: A61K39/395
Filed: 2011-09-30
Abstract: Disclosed herein are non-aqueous high concentration suspension formulations, comprising: a. a vehicle, consisting of sesame oil as a hydrophobic agent and ethyl oleate as a viscosity reducing agent; and b. an antibody formulated with an excipient, wherein the antibody may be an anti-TNFα antibody.
Patent NZ-736332-A (NZ)
Title: Occupancy or vacancy indicating system
Inventor: LELIEVRE MARCEL XAVIER
IPC: G08B7/06
Filed: 2016-10-20
Abstract: The invention solves the problem of safely tracking vacancy or occupancy of a building. An increase of multi-storied buildings in cities around the world has exacerbated the problem of tracking occupancy or vacancy of buildings in a safe and efficient manner during emergencies. In some emergencies such as a fire, the building may need to be safely evacuated. In other emergencies, such as an impending terrorism threat, the building may need to be locked down until the situation returns to normal. The invention resides in an occupancy or vacancy indicating system comprising an indicating assembly comprising a controller and an indicator to indicate an occupancy or vacancy related status of one or more areas of a space; the controller being arranged to set the status of the indicator, a receiver for receiving one or more signals from a remotely located device, the receiver being in communication with the controller to initialise the indicating assembly to thereby indicate an activated status in response to receiving one or more signals from the remotely located device, and a sensor positioned in close proximity to the indicating assembly, the sensor being in communication with the controller to modify the activated status of the indicator upon sensing occupancy or vacancy of the one or more areas of the space and display a corresponding occupancy or vacancy related status wherein the controller is arranged to modify said statuses of the indicator only after receiving the one or more signals from the remotely located device.
Patent NZ-753260-A (NZ)
Title: Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
Inventor: SCHWAEBLE HANS-WILHELM
IPC: A61K45/00
Filed: 2017-10-12
Abstract: In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing Immunoglobulin A Nephropathy (IgAN). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complement activation.
Patent NZ-753307-A (NZ)
Title: Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
Inventor: PETIT ROBERT
IPC: C12N15/74
Filed: 2017-11-30
Abstract: Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.
Patent NZ-761254-A (NZ)
Title: Sealing element for prosthetic heart valve
Inventor: LEVI TAMIR
IPC: A61F2/24
Filed: 2018-08-10
Abstract: An implantable prosthetic valve that is radially collapsible to a collapsed configuration and radially expandable to an expanded configuration includes an annular frame having an inflow end, an outflow end, and a longitudinal axis. A leaflet structure is positioned within the frame and secured thereto, and a sealing element is secured to the frame. The sealing element includes a first woven portion extending circumferentially around the frame. The first woven portion includes a plurality of interwoven filaments. The sealing element further includes a second woven portion extending circumferentially around the frame and spaced apart from the first woven portion along the longitudinal axis of the frame. At least a portion of the filaments exit a weave of the first woven portion and form loops extending radially outwardly from the frame, and extending in the downstream direction along the longitudinal axis of the frame to the second woven portion. The valve provides improved paravalvular sealing.
Patent PT-100112-A (PT)
Inventor: JONES RONALD L
IPC: A01N43/90
Filed: 1992-02-10
Abstract: Disclosed are solid oxidizer compositions that provide either hypochlorous or hypobromous acid for disinfecting water systems comprising either of the following mixtures: a) approximately 50-99.99 % by weight of trichloro-s-triazinetrione and 0.01-50 % by weight of glycolurils of structure (I) wherein R and R1 are members selected from the group consisting of hydrogen, lower alkyl radicals of from 1-4 carbon atoms and phenyl, and X is selected from the group consisting of hydrogen, chlorine and bromine and a, b, c, d and e are integers of from 0-1; and b) approximately 50-99.99 % by weight of trichloro-s-triazinetrione, .01-50 % by weight of glycolurils of the above structure a) and 0-20 % by weight of an alkali bromide salt. Also disclosed is the addition of lazurite to the above compositions.
Patent PT-103262-A (PT)
Title: Tensioning system for carbon fiber reinforced polymer (CFRP) laminate includes metallic plates that are provided with fixation screws
Inventor: DE MOURA RITA MARIA DIOGO DE C
IPC: E21D21/02
Filed: 2005-04-19
Abstract: Metallic plates of adequate geometry are provided with fixation screws. The plates provide tension to a carbon fiber composition comprising the CFRP polymer.
Patent PT-115472-A (PT)
Title: Processo de produção de um teto falso ignífugo e teto falso ignífugo por ele obtido
Inventor: MIGUEL ANGEL RODRIGUEZ BLANCO
IPC: E04F13/10
Filed: 2019-04-23
Abstract: A PRESENTE INVENÇÃO DIZ RESPEITO A UM PROCESSO DE PRODUÇÃO DE UM TETO FALSO IGNÍFUGO QUE COMPREENDE 5 ETAPAS CONSECUTIVAS, CONCRETAMENTE A ETAPA I. PREPARAR UMA FOLHA EXTERIOR (1) DE MADEIRA DO TETO FALSO, A ETAPA II. DE COLAR A FOLHA EXTERIOR (1) A UM PAINEL (2), A ETAPA III. DE CORTAR A FOLHA EXTERIOR (1) COLADA AO PAINEL (2), PRODUZIDA NA ETAPA II., EM PLACAS (3) COM AS MEDIDAS PRETENDIDAS, A ETAPA IV. APLICAR PELO MENOS UMA CAMADA DE FUNDO IGNÍFUGO (4) EM TODA A SUPERFÍCIE EXTERIOR DE CADA UMA DAS RESPETIVAS PLACAS (3) E A ETAPA V. DE APLICAR PELO MENOS UMA CAMADA DE VERNIZ IGNÍFUGO (5) EM TODA A SUPERFÍCIE EXTERIOR DE CADA UMA DAS RESPETIVAS PLACAS (3).
Patent RU-94017473-A (RU)
Inventor: BYKADOROV N U
IPC: C01F7/56
Filed: 1994-05-13
Abstract: FIELD: production of chloroaluminium-containing coagulant. SUBSTANCE: proposed method involves chemical dissolution of metal aluminium in 5-10 % solutions of hydrogen chloride acid. The process is followed by electrolysis thus prepared solution within 5-30 h. Said electrolysis is carried out on aluminium electrodes, alternating current having frequency 50 Hz is used, density of said current is A/dm. Natural bischofite is used at stage of preparing coagulant, said bischofite is mixed with product which have been electrically treated at their volume ratio (0.8-0.2)-(0.2-0.8). EFFECT: improved efficiency of the method.
Patent RU-94028999-A (RU)
Inventor: MOSKALENKO V Z
IPC: A61B5/02
Filed: 1994-08-03
Abstract: FIELD: medicine. SUBSTANCE: acute appendicitis is recognized by deep palpation of stomach in the right iliainguinal area for presence or absence of pulse at right common illiac artery. The absence of pulse of iliac artery supports in favour of acute appendicitis, and the diagnosis is considered as nonconfirmed at the presence of carotid pulse. EFFECT: provides high diagnostic accuracy.
Patent RU-94043648-A (RU)
Title: Composition for bitter "dushistaya"
Inventor: NORKIN V F
IPC: C12G3/06
Filed: 1994-12-23
Abstract: FIELD: alcoholic beverage industry. SUBSTANCE: composition of bitter contains the following ingredients for 1000 dal of prepared product: clove, 0.2-0.4 kg; sweet clover, 0.5-0.6 kg; coriander, 1.0-1.2 kg; peppermint, 1.0-1.2 kg; parsnip, 0.3-0.5 kg; dill, 1.0-1.2 kg; granulated sugar, 110.0-130.0 kg; color, 30.0-35.0 kg; orange oil, 0.015-0.020 l; aqueous-alcohol liquid, the balance. EFFECT: broadened assortment.
Patent RU-94045510-A (RU)
Inventor: MENZHERES L T
IPC: C01F7/04
Filed: 1994-12-28
Abstract: FIELD: chemical materials technology. SUBSTANCE: method of synthesis of lithium aluminates with general formula LiAn•2xAl(OH)•mHO, where An idand other, x is anion charge, useful as sorbents, anion exchangers, etc., is carried out at reduced temperature (25 instead of 85 C) at by 6 times shortened process duration with operations of preparing concentrated solutions of lithium salts eliminated and possible use of low- soluble lithium salts. To do this, stoichiometric mixture of components (aluminium hydroxide and corresponding lithium salt) is treated in mill-activator until individual compound is formed. Time needed for synthesis depends on mill type and, for power-supplied apparatuses, is 5-30 min on the average. EFFECT: simplified process.
Patent RU-95100247-A (RU)
Inventor: KAPRANOV B I
IPC: G01B7/06
Filed: 1995-01-10
Abstract: FIELD: measuring technology; invention refers to nondestructive methods for testing of quality and geometric dimensions and may be used in all branches of economy where objects with coats are utilized or coat testing is conducted. SUBSTANCE: device comprises converter, generator, peak amplitude detector, indicator, frequency control unit, first storage, disbalance amplifier, unit setting reference level, amplitude control unit, analog-to-digital converter, second storage programmed in advance. Excitation input of converter is connected to output of generator, first controlling input of generator is linked to output of frequency control unit, output of converter is coupled to input of peak amplitude detector. Output of the latter is coupled to input of first storage and input of analog-to-digital converter. Output of first storage is connected to first input of disbalance amplifier which second input is linked to output of unit setting reference level. Output of disbalance amplifier is coupled to input of amplitude control unit which output is connected to second controlling input of generator. Digital output of analog-to-digital converter is linked to address input of second storage programmed in advance which output is connected to input of indicator. EFFECT: increased precision of measuring thickness of conductive coat. 1 cl, 3 dwg
Patent RU-95103180-A (RU)
Inventor: KOZHEVNIKOV V A
IPC: A61B18/02
Filed: 1995-03-06
Abstract: FIELD: medicine; surgery. SUBSTANCE: method involves cryotreatment using a special apparatus for 15 sec followed by burying the stump without bandage in purse-string suture. EFFECT: intestine aperture opening prevented; lower probability of abdominal infection.